£139.00
Description
New blood vessel formation occurs via angiogenesis or vasculogenesis, a process thought to be restricted to embryonic development. In 1997, postnatal vasculogenesis has been proposed as an important mechanism for angiogenesis via blood or bone marrow derived circulating progenitor endothelial cells (PEC) (Asahara et al, Science 1997). Consequently, PECs have been extensively studied as a potential cell therapy for the repair of damaged blood vessels. Animal studies clearly demonstrated that administration of PECs partially rescued cardiovascular dysfunction or myocardial injury with evidence for PEC contribution to new vessel growth. In most studies, PECs are defined by cell surface expression of CD34, CD133, or VEGF-R2 (KDR). Because these molecules are also present on hematopoietic progenitors, relying only on surface markers can not exclude a contamination with hematopoietic linage cells. More recently, a PEC population has been identified which shows expression of endothelial as well as progenitor, but not hematopoietic cell markers (Ingram et al, Blood. 2004;104:2752). Importantly, these cells have been tested for a high proliferative potential in clonogenic assays and additionally characterized by formation of functional blood vessels in vivo (Yoder et al, Blood. 2007;109:1801).
Endopan PRO Kit is provided with FBS growth supplement (pre-screened and tested for progenitor cells) and additional supplements in separate sterile packing. This will enable the user to prepare a medium for special applications.